Oncogenic mutations in key MAPK components drive up to 30% of human cancers, particularly NSCLC, which is frequently initiated by mutually exclusive mutations in RTKs such as EGFR, HER2, ALK, ROS1, KRAS, and BRAF (45–48). This evidence concerns the gene BRAF and non-small cell lung carcinoma.